Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

Wenjie Liang; Yicheng Ni; Feng Chen

doi:10.18632/oncotarget.6999

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

Wenjie Liang, Yicheng Ni and Feng Chen _

PDF | HTML | How to cite

Oncotarget. 2016; 7:15444-15459. https://doi.org/10.18632/oncotarget.6999

Metrics: PDF 2295 views | HTML 3027 views | ?

Abstract

Wenjie Liang1, Yicheng Ni2 and Feng Chen1

1 Department of Radiology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

2 Radiology Section, University Hospitals, University of Leuven, Leuven, Belgium

Correspondence to:

Feng Chen, email:

Keywords: vascular disrupting agents, resistance, imaging, solutions

Received: September 27, 2015 Accepted: January 14, 2016 Published: January 24, 2016

Abstract

The emergence of vascular disrupting agents (VDAs) is a significant advance in the treatment of solid tumors. VDAs induce rapid and selective shutdown of tumor blood flow resulting in massive necrosis. However, a viable marginal tumor rim always remains after VDA treatment and is a major cause of recurrence. In this review, we discuss the mechanisms involved in the resistance of solid tumors to VDAs. Hypoxia, tumor-associated macrophages, and bone marrow-derived circulating endothelial progenitor cells all may contribute to resistance. Resistance can be monitored using magnetic resonance imaging markers. The various solutions proposed to manage tumor resistance to VDAs emphasize combining these agents with other approaches including antiangiogenic agents, chemotherapy, radiotherapy, radioimmunotherapy, and sequential dual-targeting internal radiotherapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6999

Publication Alerts

Reviews:

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

Abstract